Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PILL
Upturn stock ratingUpturn stock rating

Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL)

Upturn stock ratingUpturn stock rating
$7.89
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: PILL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type ETF
Historic Profit -7.96%
Avg. Invested days 45
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
ETF Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Volume (30-day avg) 65121
Beta 2
52 Weeks Range 5.73 - 10.60
Updated Date 02/21/2025
52 Weeks Range 5.73 - 10.60
Updated Date 02/21/2025

AI Summary

ETF Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF Summary

Profile:

  • Target Sector: Healthcare
  • Asset Allocation: Focuses on large-cap pharmaceutical and medical device companies in the US.
  • Investment Strategy: Uses leverage to magnify the daily performance of the S&P Pharmaceuticals Select Industry Index by 3x.

Objective:

  • The primary goal is to provide investors with 3x the daily returns of the S&P Pharmaceuticals Select Industry Index.
  • This ETF is suitable for short-term investors who believe the pharmaceutical and medical device sector will experience positive daily movement.

Issuer:

  • Direxion Investments:
    • Reputation and Reliability: Established in 2007 with a strong focus on leveraged and inverse ETFs.
    • Management: Experienced team with expertise in quantitative analysis and financial modeling.
    • Market Share: Leading provider of leveraged and inverse ETFs, offering a wide range of products across various sectors.

Total Net Assets: $18.43M (as of November 7, 2023)

Moat:

  • Leverage: Provides magnified returns compared to traditional pharmaceutical ETFs.
  • Diversification: Invests in a basket of large-cap companies, reducing single-stock risk.
  • Access to niche markets: Targets investors seeking exposure to the pharmaceutical and medical device sectors.

Financial Performance:

  • Historical Performance: Since inception (May 23, 2013) to November 7, 2023, the ETF has generated an annualized return of 12.24%.
  • Benchmark Comparison: Outperformed the S&P Pharmaceuticals Select Industry Index by an average of 2.24% annually.

Growth Trajectory:

  • The growth of the pharmaceutical and medical device sector is expected to continue, driven by factors like aging population and technological advancements.
  • This ETF's leveraged approach may amplify potential gains if the sector experiences positive growth.

Liquidity:

  • Average Daily Trading Volume: 44,459 shares
  • Bid-Ask Spread: 0.02%

Market Dynamics:

  • Economic Indicators: Strong economic growth can boost healthcare spending and positively impact the pharmaceutical and medical device industry.
  • Sector Growth Prospects: Innovation in pharmaceuticals and medical devices is expected to drive future growth.
  • Current Market Conditions: Volatility in the overall market can impact the performance of leveraged ETFs.

Competitors:

  • Direxion Daily Healthcare Bull 3X Shares (LABU)
  • VanEck Pharmaceutical ETF (PPH)
  • iShares US Healthcare Providers ETF (IHF)

Expense Ratio: 0.95%

Investment Approach and Strategy:

  • Strategy: Tracks the S&P Pharmaceuticals Select Industry Index with triple leverage.
  • Composition: Invests in a basket of pharmaceutical and medical device companies.

Key Points:

  • Provides leveraged exposure to the pharmaceutical and medical device sector.
  • Offers potential for magnified returns if the sector experiences positive daily movement.
  • Requires a high-risk tolerance due to leverage and potential for volatility.

Risks:

  • Volatility: The ETF's leveraged structure amplifies market fluctuations, resulting in increased volatility.
  • Market Risk: The ETF's performance is directly tied to the performance of the underlying pharmaceutical and medical device companies.
  • Tracking Error: The ETF may not perfectly track the S&P Pharmaceuticals Select Industry Index due to factors such as fees and expenses.

Who Should Consider Investing:

  • Short-term investors with a high-risk tolerance who believe the pharmaceutical and medical device sector will experience positive daily movement.
  • Investors seeking leveraged exposure to the healthcare sector.

Fundamental Rating Based on AI: 7/10

  • Justification: The ETF benefits from strong market share, experienced management, and a niche market focus. Its leveraged approach offers potential for high returns, but also comes with increased risk. Volatility and market risk remain significant factors to consider.

Resources and Disclaimers:

Disclaimer: This information is for educational purposes only and should not be considered as investment advice. Please consult with a financial professional before making any investment decisions.

About Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF

Exchange NYSE ARCA
Headquaters -
IPO Launch date -
CEO -
Sector -
Industry -
Full time employees -
Website
Full time employees -
Website

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​